Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail

Otsuka Obtains Global Rights To Two Drugs

 
• By Lisa Takagi

Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.

Sumitomo decided to prioritize other candidates than the four in the Otsuka deal amid financial challenges.
Sumitomo has decided to prioritize other R&D candidates over the four in its Otsuka alliance amid financial challenges • Source: Shutterstock

More from R&D

More from Scrip